FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.880,90 -1.282,04 (-2,13%)
Opthea Limited (OPT.AX)
| Chiusura precedente | 0,6750 |
| Aperto | 0,6650 |
| Denaro | 0,6250 x 1566800 |
| Lettera | 0,6550 x 380500 |
| Min-Max giorno | 0,6200 - 0,6650 |
| Intervallo di 52 settimane | 0,3125 - 0,8150 |
| Volume | |
| Media Volume | 723.028 |
| Capitalizzazione | 414,254M |
| Beta (5 anni mensile) | 0,73 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4600 |
| Prossima data utili | 28 feb 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 11 ott 2004 |
| Stima target 1A | 10,10 |
GlobeNewswireOpthea to Participate at the 2023 Euretina Congress
MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company’s Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization’s 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherland
- GlobeNewswire
Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference
MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company’s Chief Financial Officer will present at H.C. Wainwright’s 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023. Mr. Morris will present on Wed
- GlobeNewswire
Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)
OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of strong demand from both existing and new domestic and offshore institutional investors Opthea has accepted an additional A$10.0 million in oversubscriptions, increasing the placement size to A$20.0 million and the total size of the capital raising to A$90.0 millionThe Placement and Institutional Entitlement Offer raised approximately A$73.7mThe ful
